Protalix BioTherapeutics PLX is gearing up to announce its quarterly earnings on Thursday, 2024-11-14. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Protalix BioTherapeutics will report an earnings per share (EPS) of $0.04.
The announcement from Protalix BioTherapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Performance in Previous Earnings
In the previous earnings release, the company missed EPS by $0.05, leading to a 2.15% increase in the share price the following trading session.
Here's a look at Protalix BioTherapeutics's past performance and the resulting price change:
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | 0.02 | -0.02 | -0.03 | -0.04 |
| EPS Actual | -0.03 | -0.06 | -0.07 | -0.04 |
| Price Change % | 2.0% | -12.0% | -3.0% | -1.0% |
Stock Performance
Shares of Protalix BioTherapeutics were trading at $1.32 as of November 12. Over the last 52-week period, shares are down 9.71%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
